Company: PTHS
Filing Date: 2025-05-27
Form Type: DEFM14C
Source: 0001140361-25-020509
Chunk: 20

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-27
Form: DEFM14C
Chunk 20
---
 to occur substantially concurrently with the PIPE Financing, entry into the Royalty Agreements, as well as certain other conditions. Channel’s and LNHC’s obligations to consummate the Merger are conditioned upon the closing of the PIPE Financing immediately prior to or concurrently with the closing of the Merger.

7

TABLE OF CONTENTS

Management Following the Merger Effective as of the closing of the Merger, the combined company’s executive officers and directors are expected to be:

| Name                |     | Title                                           |
| Scott Plesha        |     | President, Chief Executive Officer and Director |
| Francis Knuettel II |     | Chief Financial Officer                         |
| Richard Baxter      |     | Director                                        |
| Todd Davis          |     | Director                                        |
| Ezra Friedberg      |     | Director                                        |
| Peter Greenleaf     |     | Director                                        |
| Dr. Richard Malamut |     | Director                                        |
| Matthew Pauls       |     | Director                                        |

Interests of Directors and Executive Officers of Channel and LNHC Interests of Channel Directors and Executive Officers in the Merger In considering the recommendation of the Channel board of directors with respect to approving the Merger, Channel stockholders should be aware that Channel’s executive officers and directors may have interests in the Merger that are different from, or in addition to, the interests of Channel stockholders generally. Interests of the directors and executive officers may be different from or in addition to the interests of the stockholders for the following reasons, among others:

| • | Todd Davis, Ezra Friedberg and Dr. Richard Malamut, existing directors of Channel, are expected to continue as directors of the combined company, and following the closing of the Merger will be eligible to be compensated as non-employee directors of the combined company pursuant to the combined company’s non-employee director compensation policy that will be put in place following the Effective Time; |

| • | Three of Channel’s directors are expected to become directors in the combined company following closing of the Merger. |

The Channel board of directors and the Special Committee were aware of these potential conflicts of interests and considered them, among other matters, in approving the Transaction Agreements and the Transactions. These interests are discussed in more detail in the sections titled “ The Merger-Interests of Channel Directors and Executive Officers in the Merger,” “ The Merger Agreement-Indemnification and Insurance for Directors and Officers” and “ Channel’s Executive and Director Compensation” beginning on pages 121,